A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Sponsor:
- Puma Biotechnology, Inc.
- Sponsor Study ID:
- PUMA-ALI-4201
- CTO #:
- 104013
- NCT Number:
- NCT06095505
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- Determine whether any biomarker correlates with alisertib response. Determine investigator-assessed efficacy in the patient population. Determine survival outcomes in the patient population. Determine the safety profile of alisertib. Update the population pharmacokinetic (popPK) profile of alisertib
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Rangel, Christopher, at rangelc@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina